GUTS
Fractyl Health
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 3
consensus rating "Strong Buy"
MACD Death Cross
Net Income Plunges
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GUTS
Fractyl Health, Inc.
A diabetes and obesity therapy research and development company
Life Science Tools and Services
08/30/2010
02/02/2024
NASDAQ Stock Exchange
107
12-31
Common stock
3 Van de Graaff Drive, Suite 200, Burlington, MA 01803
--
Fractyl Health, Inc., was incorporated under the laws of the State of Delaware on August 30, 2010. The company is a metabolic therapy company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. About 100 million people in the United States have prediabetes and obesity, and another 25 million have diabetes and are on medication, according to the Centers for Disease Control and the International Diabetes Federation. The company's goal is to develop durable disease-modifying therapies designed to provide long-term maintenance of metabolic health without the need for lifelong treatment by targeting the organ-level root causes of T2D and obesity.
Earnings Call
Q1/2025
Estimate EPS-0.5
Actual EPS-0.46
Estimate Revenue--
Actual Revenue0.00
Fractyl Health's Q1 2025 Earnings Call: Key Contradictions in Clinical Trial Progress and Regulatory Pathways
May 20,2025 03:51
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
GUTS has released its 2025 Q1 earnings. EPS was reported at -0.46, versus the expected -0.50, beating expectations. The chart below visualizes how GUTS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
